FindTrial
Sign In

WEF-001

DRUG3 trials

Sponsors

Auricula Biosciences Inc.

Conditions

Advanced KRAS- Mutant Solid TumoursAdvanced Solid TumorsAdvanced or Metastatic KRAS-mutant TumorAdvanced or Metastatic KRAS-mutant Tumor in Colorectal CancerAdvanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung CancerAdvanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma

Phase 1

An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of WEF-001 in participants with Advanced KRAS- Mutant Solid Tumours.
WithdrawnCTIS2024-518644-21-00
Auricula Biosciences Inc.Advanced KRAS- Mutant Solid Tumours
Target: 27Updated: 2025-08-04
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
RecruitingNCT07148128
Auricula Biosciences Inc.Advanced or Metastatic KRAS-mutant Tumor, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer +2
Start: 2025-07-28End: 2028-01-01Target: 110Updated: 2026-01-29
An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of WEF-001 in participants with Advanced KRAS- Mutant Solid Tumours.
Not yet recruitingCTIS2024-518644-21-01
Auricula Biosciences Inc.Advanced KRAS- Mutant Solid Tumours
Target: 27Updated: 2025-12-09